Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications

Abstract

Coronaviruses disease 2019 (COVID-19) is the most crucial threat, the world has ever witnessed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of this disease pandemic. The World Health Organization has confirmed the continuing epidemic as a worldwide public health crisis. Presently, the research on COVID-19 is even in the primitive stage. Studies on unveiling the natural route of COVID-19 infection and related pathophysiology, the biology of pulmonary airways pose a more rational restorative approach in the management of COVID-19. Thus, based on the existing facts, we methodically reviewed the efforts put forth by various research institutes, pharmaceutical companies and biotechnology firms in pulmonary delivery to prevent and control the COVID-19. This article would be valuable for the healthcare community, which is efficiently dealing with the SARS-CoV-2 crisis.

Keywords: COVID-19; Drug repurposing and disposable medical devices; Dry powders; Inhaled vaccine; Intranasal drug delivery; Pulmonary therapy.

Fig. 1

Carragelose® physically interacts with mucosal surfaces and creates a protective physical barrier to prevent binding and/or entry of the respiratory viruses into the cells.